MSGR Direxion mRNA ETF
Quote as of Apr 21, 2023 14:41 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 13.81 | Day Range | 13.81 – 13.91 |
| 52-Week Range | 13.81 – 4,621.6 | Volume | 652 |
| Avg Volume | 81 | AUM | $3.1M (Aug 27, 2026) |
| Expense Ratio | — | Yield (TTM) | — |
| NAV | — | Premium/Discount | — |
| Inception | Dec 09, 2021 | Holdings | 24 |
| Issuer | Direxion | Exchange | AMEX |
| Category | — | Index Tracked | Not stated in source data |
| CUSIP | — | ISIN | — |
| Management | Not stated in source data | ||
About this ETF
The fund, under normal circumstances, invests at least 80% of its assets in the securities that comprise the index or investments with economic characteristics similar to the securities included in the index. The index provides exposure to the performance of companies, publicly listed in the United States, Canada and Europe, that are leading the development and application of messenger RNA (“mRNA”) technology. The fund is non-diversified.
Description from the fund data provider · profile as of Aug 27, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +4.27% | -12.95% | -2.73% | -2.32% | -6.58% | — | — | — | -42.80% |
| Total return | +4.27% | -10.72% | -0.22% | +0.14% | -4.20% | — | — | — | -41.36% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through May 02, 2023. Past performance does not guarantee future results.
Fees
| Net expense ratio | — | Annual cost of a $10,000 investment | — |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 22, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 23 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | VRTX | 8.09% | 769 | $253.1K |
| 2 | BeiGene Ltd | BGNE | 7.51% | 910 | $235.0K |
| 3 | Arcturus Therapeutics Holdings Inc | ARCT | 7.45% | 8.67K | $233.0K |
| 4 | SCLX | SCLX | 6.82% | 17.43K | $213.2K |
| 5 | Alnylam Pharmaceuticals Inc | ALNY | 6.45% | 994 | $201.6K |
| 6 | PTC THERAPEUTICS INC USD 0.001 | PTCT | 6.31% | 3.67K | $197.4K |
| 7 | BIONTECH SE | BNTX | 5.76% | 1.49K | $180.2K |
| 8 | Moderna Inc | MRNA | 5.60% | 1.24K | $175.0K |
| 9 | SAREPTA THERAPEUTICS INC | SRPT | 5.30% | 1.31K | $165.8K |
| 10 | Maravai LifeSciences Holdings Inc | MRVI | 4.93% | 10.94K | $154.3K |
| 11 | Intellia Therapeutics Inc | NTLA | 4.33% | 3.79K | $135.4K |
| 12 | IONIS PHARMACEUTICALS INC | IONS | 4.10% | 3.55K | $128.2K |
| 13 | ARROWHEAD PHARMACEUTICALS IN | ARWR | 3.68% | 3.85K | $115.1K |
| 14 | AVIDITY BIOSCIENCES INC | RNA | 3.67% | 7.29K | $114.7K |
| 15 | CureVac NV | CVAC | 3.38% | 13.32K | $105.8K |
| 16 | DYNE THERAPEUTICS INC | DYN | 3.05% | 9.08K | $95.3K |
| 17 | ARBUTUS BIOPHARMA CORP NPV | ABUS | 3.00% | 31.69K | $93.8K |
| 18 | Sangamo Therapeutics Inc | SGMO | 2.26% | 43.44K | $70.8K |
| 19 | Stoke Therapeutics Inc | STOK | 1.95% | 7.15K | $60.9K |
| 20 | Gritstone Oncology Inc | GRTS | 1.94% | 23.63K | $60.7K |
| 21 | HLVX | HLVX | 1.57% | 3.55K | $49.2K |
| 22 | PROQR THERAPEUTICS NV | PRQR | 1.54% | 21.68K | $48.1K |
| 23 | PEPGEN INC | PEPG | 1.29% | 3.22K | $40.5K |
Click a ticker to see every ETF that owns it.
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | — | Paid (last 12 months) | — |
| Frequency | Irregular | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Mar 21, 2023 | Last payment | $0.3370 |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Mar 21, 2023 | — | — | $0.3370 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
Liquidity
| Volume today | 652 | Average volume | 81 |
| AUM | $3.1M | Premium/Discount | — |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for MSGR
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.